Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26741121 | 0.85 | LMNA (0.38) | LMNAALDH1A1 | |
| SCHEMBL21518282 | 0.84 | LMNA (0.32) | LMNAALOX15ALDH1A1 | |
| SCHEMBL16335543 | 0.80 | LMNA (0.65) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL6535475 | 0.80 | LMNA (0.65) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL16377876 | 0.80 | LMNA (0.65) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL128395 | 0.79 | LMNA (0.41) | LMNABLMALDH1A1 | |
| SCHEMBL11848061 | 0.79 | LMNA (0.33) | LMNA | |
| SCHEMBL46516 | 0.79 | — | — | |
| SCHEMBL20928 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-9868711-B2 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9670170-B2 | Resorufin derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160228491-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2016-08-11 | — | — | US | disclosed |
| US-9403791-B1 | Coumarin derivatives for cancer therapy | WELLESLEY COLLEGE (US) | 2016-08-02 | — | — | US | disclosed |
| US-9296712-B2 | Resorufin derivatives for treatment of oxidative stress disorders | EDISON PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
| US-8940720-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275054-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | LMNA 1757/4885BLM 4240/4885PTPN1 1905/4885 |
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | LMNA 1627/4885BLM 3752/4885PTPN1 3790/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | LMNA 1757/4885BLM 4240/4885PTPN1 1905/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | LMNA 1757/4885BLM 4240/4885PTPN1 1905/4885 |
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | LMNA 2029/4885BLM 2357/4885PTPN1 4791/4885 |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | LMNA 1627/4885BLM 3752/4885PTPN1 3790/4885 |
| US-20160228491-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF | TYR, DNPEP, ARG2 | LMNA 1187/4885BLM 1453/4885PTPN1 1191/4885 |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | LMNA 1757/4885BLM 4240/4885PTPN1 1905/4885 |
| US-20140275054-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | LMNA 2029/4885BLM 2357/4885PTPN1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.